Clinical Hold For Merck KGaA’s BTK Inhibitor Evobrutinib For MS Raises Class Safety Fears

Third To Be Hit With MS Clinical Hold

 
• By Ayisha Sharma
  
Stop sign
The Hold Means New Patients Cannot Be Treated With Evobrutinib • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D